Related Experiment Video

Updated: Nov 11, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.9K

Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines

Christudas Morais1,2, Retnagowri Rajandram3, Jade S Blakeney4

  • 1Centre for Kidney Disease Research, The University of Queensland, Translational Research Institute, Brisbane, Australia.

Plos One
|March 25, 2021
PubMed

Insights

Protease activated receptor-2 (PAR2) is reduced in renal cell carcinoma (RCC) tumors compared to normal kidney tissue. This finding suggests PAR2 is not a viable therapeutic target for treating this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Protease activated receptor-2 (PAR2) is implicated in various cancers and considered a potential therapeutic target.
  • Antagonists for PAR2 have been developed, prompting investigation into their use for renal cell carcinoma (RCC).

Purpose of the Study:

  • To investigate the expression of PAR2 in human RCC tissues and cell lines.
  • To determine if PAR2 is a suitable therapeutic target for RCC treatment.

Main Methods:

  • Tissue microarray (TMA) construction from RCC and paired normal kidney tissues.
  • Quantitative polymerase chain reaction (qPCR) and immunohistochemistry to assess PAR2 expression.
  • Analysis of PAR2 expression in RCC cell lines and primary human kidney tubular epithelial cells (HTEC) using qPCR, immunocytochemistry, and intracellular calcium mobilization assays.

Main Results:

  • TMA analysis showed an 85% decrease in PAR2 expression in RCC tissue compared to normal kidney tissue.
  • qPCR revealed a significant reduction in PAR2 mRNA levels in RCC compared to normal kidney samples.
  • All examined RCC cell lines exhibited lower PAR2 expression levels than HTEC.

Conclusions:

  • PAR2 expression is significantly reduced in RCC compared to normal kidney tissue.
  • The downregulation of PAR2 in RCC suggests it is unlikely to be an effective therapeutic target for this cancer.

More Related Videos

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

957
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.0K

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K